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Background: Langerhans cells (LC) are bone marrow-derived cells in the skin. The LC donor/recipient chimerism is
assumed to influence the incidence and severity of graft-versus-host disease (GVHD) after hematopoietic stem cell
transplantation (HSCT). In nonmyeloablative (NM) HSCT the appearance of acute GVHD is delayed when compared with
myeloablative conditioning. Therefore, we examined the development of LC chimerism in a NM canine HSCT model.
Methods: 2 Gy conditioned dogs received bone marrow from dog leukocyte antigen identical littermates. Skin biopsies
were obtained pre- and post-transplant. LC isolation was performed by immunomagnetic separation and chimerism
analysis by PCR analyzing variable-number-of-tandem-repeat markers with subsequent capillary electrophoresis.
Results: All dogs engrafted. Compared to peripheral blood chimerism the development of LC chimerism was delayed
(earliest at day +56). None of the dogs achieved complete donor LC chimerism, although two dogs manifested a 100 %
donor chimerism in peripheral blood at days +91 and +77. Of interest, one dog remained LC chimeric despite loss of
donor chimerism in the peripheral blood cells.
Conclusion: Our study indicates that LC donor chimerism correlates with chimerism development in the peripheral
blood but occurs delayed following NM-HSCT.
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Haematopoietic stem cell transplantation (HSCT) is an
essential option for therapeutic treatment of malignant
haematopoietic diseases. Nonmyeloablative (NM) HSCT
is characterized by reduced intensity and toxicity [1, 2]
and is therefore a treatment option for patients with con-
traindications (e.g. old age) who are not eligible candidates
for conventional myeloablative (M)-HSCT [3]. The suc-
cess of NM-HSCT in donor engraftment is (yet) associ-
ated with acute graft-versus-host disease (GVHD) rates
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Acute GVHD typically develops within the first 3 months
after M-HSCT and mainly affects the skin, but also the liver
and the gastrointestinal tract [5]. Following NM-HSCT the
signs and symptoms of acute GVHD are usually delayed
and arise beyond day +100 [6].
Langerhans cells (LC) are CD1a positive bone marrow-
derived dendritic cells located in the epidermis and
mucous membrane [7, 8]. They are characterised by the
presence of cytoplasmatic Birbeck granules [9]. LC are
able to deliver antigenic information of their environment
to the draining lymph nodes for presentation to the T
lymphocytes [10]. In addition, LC might play an important
role in skin GVHD [11, 12].is distributed under the terms of the Creative Commons Attribution 4.0
.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
ive appropriate credit to the original author(s) and the source, provide a link to
changes were made. The Creative Commons Public Domain Dedication waiver
ro/1.0/) applies to the data made available in this article, unless otherwise stated.
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importance in GVHD development [11, 13]. The en-
graftment kinetic of donor LC is influenced by the con-
ditioning. In conventional M-HSCT the majority of LC
are of donor origin as soon as day +40. After reduced in-
tensity conditioning the engraftment of donor LC is de-
layed and full donor LC chimerism is not detected
before day +100 [12]. However, data regarding LC kinet-
ics after NM-HSCT are rare and the correlation between
LC chimerism and development of GVHD remains to be
investigated.
For preclinical studies, especially in the field of HSCT,
the dog has proven as unique model organism for de-
cades due to high transferability potential of the gained
results to humans [2, 14]. Canines and humans show
common similarities in physiology, metabolism and
lifespan of blood cells [15]. The clinical application of
NM-HSCT in humans is based on a meanwhile well-
established canine NM-HSCT model using 2 Gy total
body irradiation for conditioning [14].
Lowering the intensity of the conditioning appears to
increase the incidence of graft rejection [16]. Therefore,
the development of new NM-HSCT regimens, e.g. appli-
cation of new immunosuppressive drugs, is required.
Hence, our present study was initially designed to assess
the impact of the new immunosuppressant everolimus
in the canine NM-HSCT model. In general occurrence
of GVHD in the canine matched-sibling NM-HSCT
model is rare, and thus the herein used experimental set-
ting is not suitable for methodical GVHD studies. How-
ever, the development of donor LC chimerism following
NM-HSCT is an observed phenomenon providing an
important issue in transplantation LC biology that can
be adequately investigated with this model.
In this study we therefore described the kinetics of
LC number and chimerism in a canine 2 Gy NM-




Experiments were approved by the regional review board
of the state Mecklenburg-Vorpommern (State Institute
for Agriculture, Food Safety and Fishery Mecklenburg-
Vorpommern, Germany; AZ: 7221.3-1.2-039/06) under
advice of the regional animal ethics committee (§15
committee). Litters of beagles were obtained from com-
mercial kennels licensed by the German Department of
Agriculture. All dogs were dewormed and immunized
against rabies, parainfluenca, leptospirosis, distemper,
hepatitis, and parvovirus. Dog leukocyte antigen (DLA)-
identical donor/recipient sibling pairs were selected on
the basis of matching for highly polymorphic DLA class
I and class II microsatellite markers [17, 18].Haematopoietic stem cell transplantation
Animals were treated according to a protocol evaluating
everolimus as new immunosuppressant in a NM-HSCT
setting [19]. Briefly, dogs were conditioned at day -1 with
2 Gy total body irradiation and received unmodified bone
marrow from DLA-identical littermates at day 0. Marrow
grafts contained a median of 3.7 × 108 (range 1.9–
11.8 × 108) total nucleated cells/kg, 6.7 × 106 (2.6–
18.2 × 106) CD34+ cells/kg and a median of 2.0 × 107
(range 0.9–7.9 × 107) CD3+ cells/kg (Table 2). Immuno-
suppression consisted of cyclosporin A (15 mg/kg BID)
from day -1 to +35 and everolimus (0.25 mg BID) from
day 0 to +27.
Preparation of Langerhans cells
Tissue samples of the skin were obtained from the neck of
9 dogs before and after HSCT on days +28, +56 and +105
under general anaesthesia (punch biopsies, 2 × 50.5 mm2).
In long-term chimeras specimen of dermal tissue were also
taken after day +105. Tissue samples were disinfected in
povidone-iodine (Mundipharma, Limburg/Lahn, Germany),
bleached with sodium thiosulfate (0.05 %, Sigma Aldrich,
Hamburg, Germany) and washed in phosphate buffered sa-
line (PBS, Biochrom AG, Berlin, Germany). The epidermis
was separated from the dermis by digestion with dispase
(2.24 U/ml, Roche, Mannheim, Germany) at 4 °C overnight
and at 37 °C (water bath) for one additional hour. Subse-
quently the epidermis was incubated at 37 °C for 30 min in
trypsin (0.25 %, Biochrom AG) with DNase (10 μl/ml,
Roche) to obtain a single cell suspension.
Single cells were labelled with a monoclonal mouse
anti-canine CD1a antibody (clone CA9.AG5; kindly pro-
vided by Dr. P.F. Moore, School of Veterinary Medicine,
University of California). Afterwards cell suspension was
incubated with a goat-anti-mouse MicroBead (Miltenyi
Biotec, Bergisch Gladbach, Germany). The labelled LC
were enriched by MiniMACS device using large cell col-
umns (Miltenyi Biotec).
Blood preparation and chimerism analyses
Before and after HSCT peripheral blood of the recipients
was taken weekly up to day +77 and in larger intervals
thereafter for analyses of the donor/recipient haematopoi-
etic chimerism. Granulocytes and peripheral blood mono-
nuclear cell (PBMC) fractions were separated by standard
Ficoll-Hypaque density gradient centrifugation (density
1.074 g/ml).
Genomic DNA of LC was isolated using Genomic DNA
from Tissue-Kit (Macherey-Nagel, Düren, Germany). Gen-
omic DNA of granulocytes and PBMC was isolated using
Nucleobond CB 100-Kit (Macherey-Nagel). Subsequently,
polymorphic tetranucleotide repeats were amplified by
PCR using commercially fluorescein-labelled primers
(BioTez Berlin-Buch GmbH, Berlin, Germany) according
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capillary electrophoresis as described elsewhere [20].
Statistics
The Mann-Whitney U-Test was performed to compare
LC cell counts between dogs that rejected the graft and
long-term chimeras. Data of LC chimerism versus chime-
rism in the peripheral blood were analysed by the Wilcoxon
test. Correlations between LC chimerism and chimerism in
the peripheral blood compartments were evaluated using
the Spearman’s rank correlation coefficient. Probability
of p < 0.05 was considered significant.
Results
Cell purity and yield
Punch biopsies of the skin from 9 dogs were obtained
before and on days +28, +56 and +105 after NM-HSCT.
Flow cytometric analyses of isolated LC revealed a purity
of CD1a positive cells of median 91 % (range 28–97 %)
(Fig. 1). Absolute LC cell counts showing a median of
3.0 × 104 (range 0.8–13.5 × 104) per 100 mm2 biopsy
were obtained before HSCT. After transplantation a de-
crease in LC to a median of 1.5 × 104 (range 0.3–5.6 × 104)
was detected at day +28. Normal counts of 3.0 × 104 could






















Fig. 1 Representative flow cytometric analysis of CD1a expressing
epidermal canine Langerhans cells (LC). a Forward scatter (FSC) and
side scatter (SSC) characteristics of canine LC. b FACS dot plot showing
a purity of 95 % CD1a expressing LC after isolation with
MiniMACS technologyLC counts between dogs that rejected the graft and long-
term chimeras were not observed.
To verify that the enriched CD1a positive cells were true
LC, electron microscopic identification of LC-characteristic
Birbeck granules were performed (Fig. 2).
Chimerism
All dogs initially engrafted (Table 2). Three dogs
(No. 1, 8, 9) rejected their grafts before day +100
(days +70, +70, +91). Dog no. 6 had a late rejection
more than 1 year after HSCT (day +391). One animal
(No. 2) died at day +60 due to an infection. At day +28
the donor chimerisms in the granulocyte and PBMC com-
partments were median 55 % (24–100 %) and 26 % (14–
58 %) in all dogs, respectively. In none of the animals LC
donor chimerism could be demonstrated at that time.
First LC donor chimerism was detected by day +56 in
the dogs (No. 3, 4, 5, 7) that experienced a stable long-
term chimerism in the granulocytes and PBMC com-
partments as well as in the dog that died. The median
LC donor percentage of these five animals amounted to
6 % (2–42 %) at that time. Subsequently, a gradual
increase in donor LC chimerism over the time was
observed (exemplified by dog No.3 in Fig. 3a). The two
dogs (No. 3, 4) that developed a full donor chimerism in
the peripheral blood by days +77 and +91 also achieved
the highest level of donor LC chimerism. Dog No. 4
showed the most rapid increase in donor LC percentage,
and suffered as the only one from acute GVHD starting
by day +70.
The dog (No. 6) that experienced late rejection showed
first detectable LC chimerism not until day +112 although
a donor chimerism in granulocytes and PBMC of 58 %
and 40 % was already present at day +56. Interestingly,
despite a subsequent decline in donor chimerism in the
peripheral blood to 0 %, a constantly increasing LC donor
chimerism up to 36 % (day +469) was observed (Fig. 3b).
In contrast, in the dogs that rejected their grafts before
day +100 LC of donor type could not be detected during
the complete observation period.
In summary, donor LC chimerism was significantly lower
than donor chimerism in the PBMC or granulocytes com-
partments (day +56: p = 0.011 each). Furthermore, there
was a strong correlation between the PBMC donor
chimerism and the donor chimerism in LC (day +56:
r = 0.7, p = 0.038). Dogs that showed PBMC donor
chimerism < 11 % at day +56 experienced early graft
rejection and had no donor-derived LC at any time
point. However, PBMC donor chimerism of 20–40 %
at day +56 resulted subsequently in increasing LC donor
chimerism despite decreasing PBMC chimerism. Only
PBMC donor chimerism ≥ 50 % at day +56 correlated to
high-level long-term engraftment in the peripheral blood
and in the LC.
Table 1 Langerhans cell counts and purity following isolation and enrichment

























No. 1 2.3 69.4 1.5 81.2 0.8 82.2 0.4 80.5 n.d. n.d. n.d. n.d.
No. 2c 1.9 93.2 0.8 79.2 3.8 87.5 c c c
No. 3 2.0 41.5 0.3 69.0 1.5 68.6 1.9 68.2 4.1 84.1 6.4 92.7
No. 4 0.8 82.4 1.5 73.2 1.1 71.9 4.3 78.4 7.1 88.7 10.5 94.3
No. 5 13.5 92.0 5.6 89.8 11.6 92.7 9.7 96.7 n.d. n.d. 9.0 94.2
No. 6 3.0 27.7 2.0 34.0 3.0 66.8 1.5 67.0 1.1 86.7 6.4 93.2
No. 7 4.5 96.7 3.4 72.9 7.2 87.5 0.3 78.1 4.5 93.3 4.1 92.2
No. 8 5.3 97.3 0.8 79.1 5.3 90.9 6.0 87.5 8.6 92.1 1.9 87.2
No. 9 4.1 91.2 1.9 87.2 2.6 93.5 3.4 89.2 6.0 90.0 n.d. n.d.
Median 3.0 91.2 1.5 79.1 3.0 87.5 2.7 79.5 5.3 89.4 6.4 93.0
acell counts per 100 mm2; bpurity = % of CD1a + cells; cdied day +60; n.d. not determined
Fig. 2 Electron microscopic image of a Langerhans cell. The figure insert shows a characteristic Birbeck granule (black arrow)
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Table 2 Graft composition and donor percentages of mononuclear cells of the peripheral blood (PBMC) and Langerhans cells (LC)
after transplantation
Dog Graft composition Donor chimerism [%]
d +28 d +56 d +104-112 d +140-280 d > +280 rejection
TNC [x108] CD34 [x106] CD3 [x107] PBMC LC PBMC LC PBMC LC PBMC LC PBMC LC (day)
No. 1 2.7 4.0 0.9 26.3 0.0 7.7 0.0 0.0 0.0 n.d. n.d. n.d. n.d. +70
No. 2 6.4 13.7 3.7 41.0 0.0 36.4 1.9 b b b died d + 60
No. 3 3.7 8.2 2.0 31.0 0.0 67.4 6.3 100.0 16.5 100.0 55.4 100.0 88.6 no
No. 4 1.9 3.6 1.8 17.8 0.0 64.1 41.9 100.0 88.5 100.0 90.0 100.0 95.6 no
No. 5 11.8 10.3 7.9 31.7 2.0a 49.7 16.3 63.9 13.9 n.d. n.d. 80.1 81.4 no
No. 6 6.2 18.2 3.4 58.1 0.0 39.9 0.0 41.1 12.1 7.7 17.0 0.0 35.9 +391
No. 7 7.6 6.7 3.5 25.9 0.0 21.1 2.3 92.3 3.8 25.4 6.2 17.5 22.7 no
No. 8 2.2 2.6 1.1 14.7 7.2a 3.1 7.2 5.0 5.1 0.0 7.9 0.0 5.0 +70
No. 9 3.1 3.0 1.8 14.0 0.0 10.5 0.0 0.0 0.0 0.0 0.0 n.d. n.d. +91
Median 3.7 6.7 2.0 26.3 0.0 36.4 2.3 52.5 8.6 16.6 12.5 48.8 58.7
n.d. not determined
aLC chimerism test results for these dogs were already 3 % (No. 5) and 7 % (No. 8) before transplantation despite repeated testing. Therefore, d + 28 chimerism
might be considered as not present
bdied day +60
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The aim of this study was to characterize the development
of LC donor chimerism in the skin after NM-HSCT. For
this purpose skin biopsies were taken from 9 transplanted
dogs before and at different times after NM-HSCT.
Studies describing the kinetic of LC chimerism after
myeloablative or reduced-intensity conditioning were
conducted previously [12, 13], but data analysing LC
chimerism following NM-HSCT still remain rare.
The herein gained results showed a moderate reduc-
tion of LC counts following NM-conditioning. The cell
number decreased from day 0 to +28 by half (1.5 × 104/
100 mm2) and recovered to the initial value at day +56. In
myeloablative regimens a LC nadir of 0.2 × 104/100 mm2
during the first month was observed and the LC count in-
creased to its normal level within 4-12 months after
HSCT [21, 22]. These results demonstrated a considerably
lower decrease and a faster recovery of LC numbers after
NM-HSCT when compared to the kinetics seen in mye-
loablative regimens.
The donor LC chimerism following NM-HSCT increased
slowly. In none of the examined dogs donor LC were de-
tectable until day +56. Even at day +105 the present LC
were mainly of host origin and the development of LC
chimerism was not finished within 1 year after HSCT. In
contrast, data from myeloablative studies certainly had
shown a rapid replacement of host LC by donor derived
LC as early as day +56 after HSCT [13]. The retardation in
donor LC engraftment in our NM-HSCT study was even
more pronounced than the delay previously reported after
reduced-intensity conditioning, where by day +100 the
majority of LC were donor in origin [12]. Previous studies
demonstrated that the recruitment of circulating LCprecursors does not only depend on proinflammatory
chemokines as CCL20, but also on available LC sites in
the epidermis [11, 23]. We assume that the availability
of LC sites in the epidermis was reduced due to a less
efficient depletion of host LC by NM-conditioning. There-
fore, the recruitment of donor LC precursor could be
hampered, beeing the reason for a delayed donor LC
engraftment after NM-HSCT compared to myeloablative
regimens.
In addition, a small fraction of LC is able to perform
in situ proliferation [23–25]. This self-reproducing capacity
may explain why the reduction of LC number by half was
not followed by a 50 % LC donor chimerism after reaching
initial cell counts in our study.
We also analysed the development of donor chimerism
in LC comparatively to the ratio seen in granulocytes
and PBMC. The significantly delayed donor LC engraft-
ment in our dogs is in accordance with the reduced LC
chimerism compared to DC chimerism in peripheral
blood or the bone marrow as described in a current
NM-HSCT study [26]. Dog No. 6 which experienced late
graft rejection even displayed a continuous increase of
LC donor chimerism, whereas chimerism in peripheral
blood was not detectable any longer. This observation is
potentially caused by the ability of LC to proliferate in
the epidermis [23–25]. Furthermore, dogs showing a
100 % donor chimerism in granulocytes and PBMC also
reached the highest LC donor chimerism. Correlation
analysis confirmed a strong relationship between LC
and PBMC chimerism in our study. In contrast, in pre-
vious publications no correlation between dendritic cell
chimerism in the blood and in the skin has been
described [11, 12].
Fig. 3 Chimerism kinetics of Langerhans cells (LC) in comparison to the peripheral blood chimerism. Development of LC donor chimerism (bars)
compared with donor chimerism of PBMC (solid line) and granulocytes (dotted line) after 2 Gy nonmyeloablative HSCT in two dogs. a Dog No. 3
with full donor chimerism in peripheral blood. Continuously increasing LC donor chimerism starting at day +56 after HSCT at a time when the
dog experienced strong engraftment in the peripheral blood. Donor chimerism of LC developed delayed compared to donor chimerism in the
peripheral blood and did not achieve the peripheral blood levels during the observation period b Dog No 6 with initial engraftment and
subsequent late graft rejection. Despite high initial donor chimerism levels in the peripheral blood of 82 % (granulocytes d +28) and
62 % (PBMC d +21) first LC donor chimerism was not detected before day +112 probably as a consequence of decreasing peripheral
blood chimerism levels starting 4 weeks after HSCT. Interestingly, although donor chimerism values of the peripheral blood continuously
declined and the graft was eventually rejected at day +391 a continuously increasing LC donor chimerism was observed also beyond the
date of graft rejection
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transplantation. The GVHD occurred at day +70 and the
dog rapidly developed a high LC donor chimerism until
day +105. Whether the earlier onset of donor LC chime-
rism has triggered GVHD, or whether the development
of acute GVHD may have facilitated the rapid replace-
ment of host LC with donor derived LC cannot be
concluded from this single case.
Conclusions
Our study indicates that LC chimerism kinetics are
delayed following NM-HSCT compared to chimerismdevelopment in the peripheral blood. Highest donor LC
engraftment rates were observed in dogs with full donor
peripheral blood chimerism and the LC chimerism
correlates with the chimerism in PBMC. The kinetic of
LC chimerism after NM-HSCT seems to be delayed in
comparison to published data on the development of
LC chimerism after myeloablative and reduced-intensity
conditioning as well. Recipient LC are present in the
skin even 1 year after NM-HSCT. Whether this differ-
ence in the kinetic of LC chimerism might be respon-
sible for the delayed onset of acute skin GVHD following
NM-HSCT remains to be investigated in future studies.
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